The oral PCSK9 inhibitor enlicitide decanoate achieved 58% LDL-C reduction in patients with heterozygous familial hypercholesterolemia, offering a potential alternative to injectable therapies.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Propensity-matched analysis of over 80,000 patients reveals bariatric surgery nearly doubles five-year esophageal complication rates compared with GLP-1 RA therapy.